How to Interpret Your Bloodwork on TRT: Key Labs and Their Meaning

Written by Adam Maggio | Medically reviewed by Dr. Mitchell Ross, MD, ABAARM

When on TRT, regular bloodwork monitoring helps optimize therapeutic effects and minimize risks. Key labs to track include total and free testosterone, estradiol, hematocrit, and PSA, with target ranges individualized based on lab standards and clinical context.

Understanding Testosterone Levels on TRT

Target serum testosterone on TRT usually falls between 500 to 700 ng/dL, depending on the lab's reference range. For example, the Endocrine Society’s guidelines suggest maintaining serum testosterone in the mid-normal range for healthy young men. A level consistently over 1000 ng/dL raises concerns for supraphysiologic dosing and potential side effects such as polycythemia or gynecomastia.

Free testosterone measurement complements total testosterone because around 2-3% of testosterone is unbound and biologically active. Free testosterone levels of approximately 9-30 ng/dL are typical in eugonadal men. Testing both helps discern issues like high SHBG, which could bind excess testosterone and hide symptoms despite normal total levels.

Timing Matters: When to Draw Labs

For injectable testosterone enanthate or cypionate given weekly at 100-150 mg, bloodwork should be drawn mid-week, around day 3-4 post-injection, to capture near-peak levels. Testing on the day before the next injection can underestimate peak testosterone and mislead dose adjustments. For daily transdermal TRT (1% testosterone gel, approximately 50 mg/day), random morning labs work due to steady absorption.

Estradiol: Balancing Benefits and Risks

Estradiol (E2) usually rises during TRT because testosterone converts to estradiol via aromatase enzymes, especially in adipose tissue. Clinicians aim to maintain E2 levels between 20-40 pg/mL. Levels below 20 pg/mL may cause joint pain, low libido, and mood symptoms. Excess E2 (>50 pg/mL) can lead to water retention, gynecomastia, or emotional lability.

Research by Dr. Shalender Bhasin highlights the importance of monitoring estradiol, as patients with suppressed E2 during aromatase inhibitor therapy sometimes report persistent sexual dysfunction, despite normal testosterone. Thus, indiscriminate use of aromatase inhibitors is discouraged—only consider them if symptoms and labs consistently reflect high estrogen.

Hematocrit and Hemoglobin: Watch for Polycythemia

TRT often elevates hematocrit due to testosterone’s stimulation of erythropoiesis. Normal hematocrit values are approximately 40-50% for men; values above 54% increase the risk of thrombosis.

Higher doses, such as 200 mg weekly testosterone injections, tend to elevate hematocrit more significantly than lower doses. Patients with baseline hematocrit above 50% or smoking history are at greater risk. Studies by Corona et al. (2016) note that therapeutic phlebotomy or lowering the TRT dose effectively manage polycythemia.

Prostate-Specific Antigen (PSA) Monitoring

Prostate cancer screening remains controversial on TRT. Baseline PSA should be measured before initiating TRT and monitored every 6-12 months thereafter. A rise greater than 0.75 ng/mL/year or exceeding 4.0 ng/mL warrants urological referral.

Most men on TRT show minimal PSA changes, but patients with a history of prostate hyperplasia or cancer require more cautious surveillance, as noted by studies from Morgentaler and Traish (2013).

Other Labs to Track

Comparison: Injectable vs. Topical Lab Variability

Injectable testosterone administers higher single doses with peak-trough fluctuations, causing variable lab levels depending on timing. By contrast, topical gels provide steadier absorption, resulting in less fluctuation but generally lower peak testosterone. This difference guides the timing of labs and interpretation of results.

For instance, a patient on 100 mg injectable testosterone weekly may measure 750 ng/dL mid-week, but levels could drop below 350 ng/dL just before the next dose. In contrast, daily 50 mg transdermal doses maintain a more constant level around 400-600 ng/dL.

Actionable Takeaway: Optimize Your TRT with Targeted Lab Monitoring

Order serum total testosterone, free testosterone, estradiol, hematocrit, and PSA every 3-6 months during the first year, then biannually if stable. Draw labs mid-cycle for injectables to capture peak serum concentrations. Adjust dose to maintain testosterone between 500-700 ng/dL and estradiol around 30 pg/mL. If hematocrit exceeds 52-54%, reduce dose or consider phlebotomy. Reassess clinical symptoms alongside labs to tailor therapy safely and effectively.